Heat and immunotherapy join forces against bile duct cancer
NCT ID NCT06440993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participants who first receive the heat treatment to clear bile duct blockages, then undergo chemotherapy plus durvalumab. The main goal is to see how many patients are alive after 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug), gemcitabine, cisplatin, and radiofrequency ablation (a heat treatment)
- What this could lead to
- If successful, this combination could offer a new treatment option that extends survival for people with advanced bile duct cancer.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The added immunotherapy could cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Krankenhaus Nordwest
RECRUITINGFrankfurt, 60488, Germany
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
-
UKSH Campus Lübeck
RECRUITINGLübeck, Germany
-
Uniklinik RWTH Aachen
RECRUITINGAachen, Germany
-
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
RECRUITINGMainz, Germany
-
Universitätsklinik Münster
NOT_YET_RECRUITINGMünster, Germany
-
Universitätsklinikum Bonn
RECRUITINGBonn, Germany
-
Universitätsklinikum Düsseldorf
RECRUITINGDüsseldorf, Germany
-
Universitätsklinikum Köln
RECRUITINGCologne, Germany
-
Universitätsmedizin Göttingen
RECRUITINGGöttingen, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can matching drugs to tumor genes beat biliary cancer?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?
- Zapping spreading tumors could extend life on current cancer drugs
- Engineered immune cells take aim at two cancer targets in hard-to-treat bile duct cancers
- New drug duo takes on tough liver cancers
- New combo therapy aims to stop bile duct cancer return after surgery